This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Catégorie : Network News
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
Dr. Ratmir Derda’s achievements were recently recognized with an award at BioAlberta’s 2021 Awards Gala.
Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
GlycoNet received a NSERC PromoScience grant and partnered with the Centre for Mathematics, Science and Technology Education to develop resources that educators can use to teach the science behind vaccines and engage students in critical thinking.
A carbohydrate-derived drug shows promise as a treatment to slow progression of the most common form of muscular dystrophy.
Read about the future of glycomics in this op ed by GlycoNet board chair Karimah Es Sabar, republished from the Hill Times. Canada has a tremendous opportunity with continued investment in glycomics to establish global leadership and economic prosperity while at the same time solving some of the world’s most pressing challenges in health and environmental sustainability.
In our new report: Why glycomics, the study of sugars on cells, is at the centre of a new surge of scientific and industry interest.
GlycoNet researchers have made exciting advances in understanding Alzheimer’s disease and are developing a potential therapeutic strategy.